Anti-nucleolin aptamer AS1411: an advancing therapeutic [PDF]
Frontiers in Molecular Biosciences, 2023 Targeted therapy is highly desirable, as it allows for selective cytotoxicity on diseased cells without off-target side effects. Nucleolin is a remarkable target for cancer therapy given its high abundance, selective presence on the plasma membrane, and ...
Alexander Van den Avont +1 more
doaj +2 more sources
Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting
Pharmaceuticals, 2021 We have designed AS1411-N6, a derivative of the nucleolin (NCL)-binding aptamer AS1411, by adding six nucleotides to the 5′-end that are complementary to nucleotides at the 3′-end forcing it into a stem-loop structure. We evaluated by several biophysical
André Miranda +2 more
exaly +3 more sources
Insights into the binding mode of AS1411 aptamer to nucleolin
Frontiers in Molecular Biosciences, 2022 AS1411 aptamer can function as a recognition probe to detect the cell surface nucleolin overexpressed in cancer cells, however, little is known about their binding process.
Lihua Bie, Fuze Jiang, Lianjun Zhang
exaly +3 more sources
Aptamer-engineered NIR-II Ru-doped carbon quantum dot nanozyme for photoacoustic imaging-guided synergistic photothermal and catalytic cancer therapy [PDF]
Journal of NanobiotechnologyCarbon quantum dot (CQD)-based nanozymes have attracted growing interest for advanced biomedical applications owing to their superior catalytic activity, photostability, and biocompatibility. However, the rational design of a multifunctional nanoplatform
Yumin Hao +8 more
doaj +2 more sources
AS1411-Bivalent-Cholesterol-Anchor Equipped with Zinc Phthalocya-Nine Enables NK Cells Derived Exosomes to Realize Effective Tumor-Tropism Photodynamic Therapy [PDF]
PharmaceuticsBackground/Objectives: Benefiting from their outstanding tumor-penetrating ability and cytotoxic proteins and cytokines, natural-killer-cell-derived exosomes (NEX) show great potential for cell-free tumor immunotherapy.
Yuchen Qi +7 more
doaj +2 more sources
Extracellular Vesicle‐Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood‐Tumour Barrier Formation [PDF]
Journal of Extracellular VesiclesGlioblastoma (GBM) remains a significant therapeutic challenge. While GBM‐derived extracellular vesicles (EVs) are known to remodel the normal blood‐brain barrier (BBB) into a blood‐tumour barrier (BTB), the underlying mechanism is largely not understood.
Hongzhen Chen +7 more
doaj +2 more sources
Synthesis and Evaluation of AS1411-Lenalidomide-Targeted Degradation Chimera in Antitumor Therapy [PDF]
PharmaceuticalsBackground: High expression of nucleolin (NCL) on the surface of tumor cells is closely associated with disease progression and poor prognosis. The aptamer–PROTAC conjugate (APC) technology provides a novel molecular design strategy for the targeted ...
Xueling Ma +11 more
doaj +2 more sources
Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer [PDF]
Advanced SciencePROteolysis TArgeting Chimeras (PROTACs) have emerged as a promising strategy for drug development targeting oncogenic proteins. Here, we report the development and characterization of dual aptamer‐based PROTACs targeting SET domain bifurcated histone ...
Yanxuan Guo +6 more
doaj +2 more sources
Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411 [PDF]
Cancer Investigation, 2018 Vivek R Sharma +2 more
exaly +2 more sources
Targeted delivery of doxorubicin and therapeutic FOXM1 aptamer to tumor cells using gold nanoparticles modified with AS1411 and ATP aptamers [PDF]
Iranian Journal of Basic Medical Sciences, 2023 Objective(s): A targeted delivery platform was prepared to co-deliver both doxorubicin (Dox) as an anticancer drug and FOXM1 aptamer as a therapeutic substance to breast cancer cells (4T1 and MCF-7) to reduce Dox side effects and increase its therapeutic
Aref Abdollahzade +6 more
doaj +1 more source